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Purpose: Different patterns of diabetic macular edema (DME) suggest different
pathogenesis and drug response. We evaluated the outcomes after intravitreal
dexamethasone (DEX) implant for DME with or without serous retinal detachment (SRD).
Methods: In this retrospective study, 22 naïve patients (23 eyes) with DME who underwent
a single DEX implant were evaluated. Based on the optical coherence tomographic pattern
of DME, 12 eyes had a cystoid macular edema pattern (Group 1) and 11 eyes had an
SRD pattern (Group 2). The best-corrected visual acuity (BCVA), central retinal thickness
(СRТ), central retinal volume (CRV), SRD height (SRDh), and intraocular pressure (IOP) were
recorded before and at two and four months after the treatment.
Results: There were no significant differences between the groups regarding
demographic, clinical data and outcomes at baseline. In Group 1, the CRT and CRV
significantly decreased at two months (P = 0.002 and P = 0.01, respectively), while the
BCVA significantly improved at four months (P = 0.03). In Group 2, the CRT and CRV
significantly improved (P < 0.01 and P ≤ 0.01, respectively) during the follow-up period. At
four months, both groups showed a recurrence of DME, Group 1 in particular (two-month
CRT reduction, –149 ± 127 µm vs four-month CRT reduction, –72 ± 174 µm; P = 0.04). The
mean reduction in CRV was significantly different at four months (Group 1, –0.49 ± 1.7
mm3 vs Group 2, –1.3 ± 1.3 mm3; P = 0.04). In Group 2, the SRDh significantly decreased
at two (P = 0.01) and four months (P = 0.01). Four cases with elevated IOP were managed.
Conclusion: DEX implants were found to be effective in different patterns of DME. The
SRD pattern may predict a longer-lasting morphologic efficacy.
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Diabetic macular edema (DME) is themain cause of
visual loss in diabetic patients.[1] Different patterns
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of nontractional macular edema have been
revealed by optical coherence tomography (OCT)
including sponge-like swelling, cystoid macular
edema (CME), and serous retinal detachment
(SRD).[2, 3] However, many eyes show more
than one macular edema pattern in OCT.[2–6]
Different patterns of CME and SRD suggest
different mechanisms of pathogenesis,[7–9]
which lead us to speculate various possible
mechanisms of drug action. At present, several
pharmacologic approaches are effective for
treating DME, including intravitreal anti-vascular
endothelial growth factor (VEGF) agents and
intravitreal steroid implants. Corticosteroids
are effective owing to their anti-inflammatory,
antiangiogenic, and blood retinal barrier (BRB)-
stabilizing properties.[10] In DME, the sustained-
release intravitreal dexamethasone (DEX) implant
was observed to be effective, requiring less
frequent repeated injections as compared to
anti-VEGFs, with common complications such as
intraocular pressure (IOP) elevation and cataract
formation/progression.[11] In an analysis of data
from a Phase II randomized controlled study
(NCT00035906), DEX implants were found to
display a similar efficacy in different patterns of
DME without reference to SRD.[12] The purpose of
this study was to analyze the safety and efficacy
of a intravitreal DEX implant in the treatment of
diabetic CME with and without subretinal fluid.
METHODS
In this retrospective study, 23 eyes of 22 diabetic
patients with clinically significant DME, as defined
by the Early Treatment Diabetic Retinopathy
Study (ETDRS),[13] were included. Nontractional
DME involving the central macula (1 mm central
subfield thickness in the OCT-modified ETDRS
grid) with a thickness ≥ 300 μm was considered.
Eyes with diffuse spongiform edema, advanced
proliferative diabetic retinopathy, other retinal
pathologies, or those who underwent previous
laser photocoagulation within six months, ocular
surgery, or intravitreal injection were excluded.
Patient data including age, sex, duration of
diabetes, and baseline glycated hemoglobin
(HbA1c) levels were recorded. A complete
ophthalmologic examination including best-
corrected visual acuity (BCVA) measurement,
slit-lamp examination, IOP measurement, and
fundus examination were performed before as
well as two and four months after the treatment.
BCVA measured by ETDRS chart was converted
into a LogMAR notation for statistical analysis.
At each visit, five HD-lines and macular cube
(512 × 128) OCT scans were performed using the
Cirrus SD-OCT 4000 (Carl Zeiss Meditec, Inc.,
Dublin, California, USA). The eligible eyes were
categorized into two groups according to the
OCT pattern of macular edema: Group 1 with CME
consisting of intraretinal hyporeflective cystoid
spaces and Group 2 with intraretinal edema
associated with SRD. The central retinal thickness
(CRT, µm) at the foveal site and the central retinal
volume (CRV, mm3) for each group were recorded.
In Group 2, the maximum SRD height (SRDh, µm)
at the fixation point was measured manually using
calipers in the “High Definition Image Analysis”
mode (HD-OCT Software version 5, Cirrus SD-OCT
4000, Carl Zeiss Meditec, Inc, Dublin, California,
USA) and was defined as the average distance
between the retinal pigment epithelium (RPE)
and the outer neurosensory retinal surface on
central vertical and horizontal scans. All OCT
scans and measurements were collected by the
same observer.
All patients received a single dose (700
µg) of DEX as a sustained-release intravitreal
implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA).
The mean BCVA, CRT, and CRV changes were
analyzed at all visits.
The study was approved by the Institutional
Review Board (IRB) of an eye clinic in Italy and
adhered to the tenets of theDeclaration of Helsinki.
An IRB approved informed consent was obtained
from all patients.
Quantitative data are presented as mean ±
standard deviation. Data from the same sample
were analyzed using the Wilcoxon test. The
differences between the two samples before and
after the implantation were assessed using Fisher’s
test for categorical variables and the Mann–
Whitney test for quantitative variables. The sample
size was determined considering a confidence
level of 95% and a confidence interval of 20.
A p-value < 0.05 was considered as statistically
significant. Statistical analysis was performed using
GraphPad Prism, version 5.
RESULTS
Twenty-three naïve eyes of 22 patients with type
2 diabetes mellitus were included. The patients
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included 6 (27.3%) women and 16 (72.7%) men,
with a mean age of 62 ± 7.7 years (range, 42–76
years). The mean overall diabetes duration was 6.4
± 3.4 years, and the HbA1C mean value was 7.5
± 1% (Table 1). All eyes were phakic with a mild-to-
moderate grade cataract. Of the 23 eyes, 12 (52%)
had a CME pattern (Group 1) and 11 (48%) had an
SRD pattern (Group 2) on OCT analysis.
There was no statistically significant difference
between the two groups in terms of age, sex, mean
diabetes duration, or HbA1C value (Table 1).
Themean overall BCVA, CRT, and CRV improved
significantly at two and four months after the DEX
implantation (Table 2).
In Group 1, the mean BCVA improved from 0.66
± 0.34 LogMAR (Snellen equivalent of 20/91) at
baseline to 0.37± 0.17 LogMAR (Snellen equivalent
of 20/47) (P = 0.06) at two months and 0.32 ±
0.19 LogMAR (Snellen equivalent of 20/42) at four
months (P = 0.03). The mean CRT decreased from
478 ± 147 µm at baseline to 329 ± 100 µm at
two months (P = 0.002) and 405 ± 132 µm at four
months (P = 0.15). The mean CRV decreased from
12.8 ± 1.9 µm3 at baseline to 11.1 ± 1.5 mm3 at two
months (P = 0.01) and 12.3 ± 1.7 mm3 at four months
(P = 0.58; Table 2).
In Group 2, the mean BCVA improved from
0.65 ± 0.43 LogMAR (Snellen equivalent of 20/89)
at baseline to 0.42 ± 0.23 LogMAR (Snellen
equivalent of 20/53) at two months (P = 0.35) and
0.39 ± 0.24 LogMAR (Snellen equivalent of 20/49)
at four months (P = 0.39). Themean CRT decreased
from 542 ± 131µm at baseline to 347 ± 97 µm at
two months (P = 0.006) and 393 ± 109 µm at four
months (P = 0.003). The mean CRV decreased from
13.7 ± 1.8 mm3 at baseline to 11.6 ± 1.5 mm3 at
two months (P = 0.007) and 12.4 ± 1.0 mm3 at four
months (P = 0.01; Table 2). At baseline and over
follow-up, no significant difference was observed in
the functional and morphologic outcomes among
the groups (P > 0.05) (Table 2).
The overall CRT reduction over two months was
significantly larger than the reduction observed
over four months (P = 0.03). In the same way,
the overall CRV reduction over two months was
significantly larger than the reduction observed
over four months (P = 0.02). The difference
between the mean change in BCVA over the
first two months and the overall four months was
not statistically significant (P = 0.26). At the last
follow-up, an improvement of three lines or more
was reported in 12 (52%) patients; 7 (58%) in the
CME group and five (45%) in the SRD group (P =
0.6). The difference between BCVA improvement
over the first two and the overall four months
within each group and among the groups was not
statistically significant (P > 0.05). In each group,
mainly in Group 1, themeanCRT andCRV reduction
after two months of follow-up were larger than
those observed four months after the implantation.
The mean reduction in CRV was significantly
different among the groups four months after the
implantation (P = 0.04) (Table 3).
In Group 2, the SRDh significantly decreased
at months 2 (P = 0.01) and 4 (P = 0.01) without a
significant difference in the mean change at two
time points (Table 4). In Group 2, a total resolution
of SRD was reported in three (27.3%) eyes and two
(18.2%) eyes at two and four months, respectively.
Of the three eyes with a resolution of SRD at
two months, only one (9%) remained without any
SRD at four months. All eyes had a resolution
of subretinal detachment without resolution of
overlying neuroretinal edema.
Three eyes (13%) had a mild IOP elevation (<25
mmHg), and only one case (3.8%) developed a high
IOP elevation (30 mmHg). All cases were medically
managed. No other ocular adverse events were
reported.
DISCUSSION
OCT is the most useful tool for diagnosing and
monitoring DME. Based on the OCT features of
DME, we focused our study on the therapeutic
efficacy of Ozurdex® on two different patterns
of nontractional DME, namely, the cystoid
pattern and the retinal detachment pattern
that occur in patients with diabetic retinopathy
with a prevalence from 47–55%[2, 4] and from 15–
31%,[2, 5, 6] respectively. In our study, both systemic
risk factors and morpho-functional data at baseline
did not show significant differences among the two
OCT-pattern groups, allowing us to evaluate the
effectiveness of the drug in two similar populations.
Moreover, Vujosevic et al reported that systemic
parameters, such as glycemic control and arterial
hypertension, did not correlate with the presence
of subretinal detachment, thus suggesting that
ocular factors might be more important in the
development of the features of DME.[14]
Intravitreal DEX implants have demonstrated
efficacy in the treatment of DME, causing both
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Table 1. Characteristics of patients and their systemic risk factors.
Total Group 1 Group 2 P-value∗







Mean age (yrs) ± SD 65 ± 10 67 ± 10 64 ± 9 0.35
Mean diabetes duration (yrs) ± SD 6.4 ± 3.4 7.2±4.1 4.5 ± 1.6 0.06
HbA1C (%) 7.5 ± 1 7.5 ± 0.9 7.4 ± 0.8 0.78
SD, standard deviation; HbA1C, glycosylated hemoglobin; DRT, diffuse retinal thickening; CME, cystoid macular edema; SRD,
serous retinal detachment
∗P-value (Mann–Whitney test); †P-value (Fisher test) between Groups 1 and 2; P-values < 0.05 were considered statistically
significant
Table 2. The mean BCVA, CRT, and CRV before and after the treatment at months 2 and 4
Total Group 1 Group 2 P-value*
Baseline BCVA (logMAR ± SD)
CRT (μm ± SD)













2𝑛𝑑 month BCVA (logMAR ± SD)
P†
CRT (μm ± SD)
P†























4𝑡ℎ month BCVA (logMAR ± SD)
P†
CRT (μm ± SD)
P†























BCVA, best corrected visual acuity; logMAR, logarithm of minimum angle of resolution; SD, standart deviation; CRT, central
retinal thickness; CRV, central retinal volume; CME, cystoid macular edema; SRD, serous retinal detachment
∗P-values (Mann–Whitney test), comparison between Groups 1 and 2; †P-value (Wilcoxon test), comparison between baseline
and follow-up data (at two and four months) for all patients, and within single groups; P-value < 0.05 was considered statistically
significant
substantial improvement in BCVA and significant
reduction of CRT.[11] In the current study, the mean
overall BCVA showed a statistically significant
improvement with a larger increase at four
months after the DEX implant. An improvement
of three lines or more was reported in 52% of
patients without differences among the groups.
These results are in line with those previously
published.[11, 15–19] We observed that the mean
BCVA of the SRD group remained lower than
that of the group with a cystoid pattern over
the follow-up period, and that the single-group
analysis showed an equal trend of functional
improvement without a significant difference in the
mean functional recovery between the groups, as
previously reported.[20] However, only the eyes
with CME showed a significant improvement in
visual acuity at four months. Gaucher et al[21]
suggested that the presence of subretinal fluid
does not seem to be a negative prognostic factor,
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Table 3. The mean change of BCVA, CRT, and CRV over four months.
Total Group 1 (CME) Group 2 (SRD) P-value∗
BCVA change (0–2 month)
(logMAR ± SD)
CRT change (0–2 month)
(μm ± SD)















(0–4 month) (logMAR ± SD)
P†
Mean CRT change
(0–4 month) (μm ± SD)
P†
Mean CRV change























BCVA, best corrected visual acuity; logMAR, logarithm of minimum angle of resolution; SD, standard deviation; CRT, central
retinal thickness; CRV, central retinal volume; CME, cystoid macular edema; SRD, serous retinal detachment
∗P-value (Mann–Whitney test), comparison between Group 1 and Group 2; †P-value (Wilcoxon test), comparison within single
groups; P-values < 0.05 were considered statistically significant
Table 4. Serous Retinal Detachment height changes over follow-up
Group 2 (11 Eyes) Baseline 2𝑛𝑑 month 4𝑡ℎ month P-value∗
SRDh (μm ± SD)
P†
SRDh change (μm ± SD)





–55 ± 59 0.38
SRDh, serous retinal detachment height; SD, standard deviation
∗P-value (Wilcoxon test), comparison between SRDh changes at different follow-ups;
†P-value (Wilcoxon test), comparison with baseline; P-value < 0.05 was considered statistically significant
while other authors have shown that the SRD
pattern had a worse prognosis on functional
recovery after treatment as compared to the CME
pattern[22–26] considering that subretinal fluid could
induce photoreceptor degradation which would
decrease its metabolism.[27]
Overall, the mean CRT and CRV showed a
statistically significant reduction at all follow-up
visits. The largest reduction in CRT and CRV was
observed at two months when DEX reached the
highest concentration in the vitreous humor.[28]
In both groups, we observed a reduction in the
mean CRT and CRV at two months, followed by
a moderate increase at four months. The group
with a cystoid pattern showed less reduction and
a significant recurrence of edema over follow-up,
while the eyes with subretinal fluid showed a
larger CRT and CRV reduction at two and four
months, and a lower recurrence of edema than the
eyes with cystoid edema. Deepening the analysis,
the SRDh significantly decreased at all follow-
up visits, showing the same trend of CRT and
CRV. In the SRD group, four patients showed a
total resolution of subretinal detachment without
resolution of overlying neuroretinal edema at
different follow-up visits. The resolution of the
subretinal fluid could appear despite persistence
or worsening of the neuroretinal swelling and
preceding or following its resolution.[21] Horii et al[9]
suggested several mechanisms causing different
OCT patterns of DME due to BRB breakdown,
including the movement of serum proteins, lipids,
528 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 4, OCTOBER-DECEMBER 2020
Dexamethasone Implant For Diabetic Macular Edema; Furino et al
blood constituents, and small molecules from or
to the cystoid spaces. The inner BRB dysfunction,
at tight junctions and transendothelial vesicular
transport in the capillary endothelial cells, leads to
neuroretinal fluid accumulation causing edema.[7]
In the cystoid pattern of DME, the occurrence
of cysts from degenerating retinal Mϋller cells
remains a subject of debate, but their role in the
formation of this pattern is certain.[29] An SRD
pattern has been postulated to be the result of
the movement of fluid from the retina to the
subretinal space.[8] The leakage of albumin into the
subretinal space brings out fluid, but this does not
explain the presence of retinal detachment when
the subretinal osmotic pressure equilibrates with
the vitreal space.[30, 31] Other mechanisms can be
involved in favoring subretinal fluid accumulation
and might be targeted by steroid therapy. In this
regard, external limiting membrane dysfunction
can promote the diffusion of proteins into the
subretinal space,[32–35] RPE pump failure found in
diabetics and favored by a hypoxic state,[36, 37] and
reduction of choroidal flow that would induce RPE
dysfunction.[38]
Corticosteroids have a wide spectrum of anti-
inflammatory and anti-edema effects. In particular,
these effects include the stabilization of the BRB
and increasing the integrity of tight junctions of
the endothelial cells of blood vessels, leading
to reduction of exudation and downregulation
of inflammation.[39] Therefore, our data suggest
a greater and more lasting improvement in the
morphologic outcomes of CRT and CRV in eyes
with an SRD pattern than eyes with CME features
after a DEX implant, probably due to a greater
stabilization of the outer BRB. Regarding safety,
few cases (4/23, 17.4%) had an IOP elevation that
could be managed pharmacologically without any
surgical approach.
This study has several limitations, including its
retrospective, short-term, open-label, uncontrolled
nature involving a relatively small number of
eyes, which precluded any evaluation of long-
term efficacy and need for Ozurdex® reinjection.
We selected only naïve patients with the aim of
evaluating the therapeutic efficacy of DEX implant
as the first treatment, even though we are aware
that these eyes are more responsive than eyes
with DME refractory to anti-VEGF.[40] A comparative
analysis of the efficacy of DEX on different OCT
patterns of DME between naïve and refractory eyes
should be performed.
In conclusion, the anatomical and functional
improvements reported in our work could suggest
a different therapeutic response of different
patterns of DME to slow-release intravitreal DEX
implants. Our findings are worthy of investigation in
order to develop customized therapies for different
tomographic patterns of DME.
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